EGFR and non-small cell lung carcinoma: Therefore, this meta-analysis aimed to assess the efficacy of osimertinib in advanced NSCLC patients with different T790M status after resistance to prior first- or second-generation EGFR-TKI treatment and to predict the subgroups that may benefit.